(Q38233105)

PubMed publication ID

25054467

31 August 2017

title

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

5

Jos H Beijnen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

author name string

Fan Lin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

Diana Hanekamp

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

Dieta Brandsma

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

Olaf van Tellingen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

language of work or name

1 reference

1 May 2013

1 reference

PubMed publication ID

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

page(s)

271-288

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

Malignant astrocytic glioma: genetics, biology, and paths to treatment

12 May 2020

cites work

1 reference

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

21 January 2018

1 reference

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

21 January 2018

1 reference

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

21 January 2018

1 reference

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.

21 January 2018

1 reference

North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

21 January 2018

1 reference

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.

21 January 2018

1 reference

Subsets of glioblastoma multiforme defined by molecular genetic analysis

21 January 2018

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

21 January 2018

1 reference

Chemotherapy delivery issues in central nervous system malignancy: a reality check.

21 January 2018

1 reference

Blood-brain barrier and chemotherapeutic treatment of brain tumors

21 January 2018

1 reference

Blood-brain barrier transporters and response to CNS-active drugs

21 January 2018

1 reference

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses

21 January 2018

1 reference

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

21 January 2018

1 reference

ABC of oral bioavailability: transporters as gatekeepers in the gut.

21 January 2018

1 reference

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

21 January 2018

1 reference

Role of transport proteins in drug absorption, distribution and excretion

21 January 2018

1 reference

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

21 January 2018

1 reference

Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds

21 January 2018

1 reference

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

21 January 2018

1 reference

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan

21 January 2018

1 reference

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

21 January 2018

1 reference

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

21 January 2018

1 reference

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

21 January 2018

1 reference

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

21 January 2018

1 reference

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

21 January 2018

1 reference

The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice

21 January 2018

1 reference

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

21 January 2018

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

Crosstalk between Pten and Ras signaling pathways in tumor development.

21 January 2018

1 reference

RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations

21 January 2018

1 reference

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

21 January 2018

1 reference

PI3K signaling in glioma--animal models and therapeutic challenges

21 January 2018

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

21 January 2018

1 reference

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

21 January 2018

1 reference

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

21 January 2018

1 reference

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

21 January 2018

1 reference

Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.

21 January 2018

1 reference

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance

21 January 2018

1 reference

Targeting mTOR globally in cancer: thinking beyond rapamycin

21 January 2018

1 reference

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

mTOR signaling: implications for cancer and anticancer therapy

21 January 2018

1 reference

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

21 January 2018

1 reference

21 January 2018

mTOR and cancer therapy

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression

21 January 2018

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

21 January 2018

1 reference

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

21 January 2018

1 reference

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

21 January 2018

1 reference

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

Current clinical development of PI3K pathway inhibitors in glioblastoma

21 January 2018

1 reference

Cancer targets in the Ras pathway

21 January 2018

1 reference

The Raf/MEK/ERK pathway: new concepts of activation.

21 January 2018

1 reference

Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency

21 January 2018

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

21 January 2018

1 reference

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

21 January 2018

1 reference

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

21 January 2018

1 reference

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

21 January 2018

1 reference

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies

21 January 2018

1 reference

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

21 January 2018

1 reference

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

21 January 2018

1 reference

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas

21 January 2018

1 reference

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma

21 January 2018

1 reference

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

21 January 2018

1 reference

Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar

21 January 2018

1 reference

Brain distribution and bioavailability of elacridar after different routes of administration in the mouse

21 January 2018

1 reference

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

21 January 2018

1 reference

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

21 January 2018

1 reference

Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein

21 January 2018

1 reference

Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents

21 January 2018

1 reference

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

Brain distribution of cediranib is limited by active efflux at the blood-brain barrier

21 January 2018

1 reference

Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics

21 January 2018

1 reference

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

21 January 2018

1 reference

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases

21 January 2018

1 reference

P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor

21 January 2018

1 reference

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme

21 January 2018

1 reference

12 December 2020

Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance

1 reference

12 December 2020

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.

1 reference

12 December 2020

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

1 reference

12 December 2020

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

12 December 2020

Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.

1 reference

12 December 2020

Identifiers

DOI

10.2217/CNS.13.15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

release_tvwgbfuxwvh25fdoisf74i53tq

12 May 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tvwgbfuxwvh25fdoisf74i53tq

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6166529&resulttype=core&format=json

12 May 2020

PubMed publication ID

25054467

1 reference